Latest News - 康诺亚生物医药科技成都有限公司

CN

Latest News Media

News

$FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies$

More

FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies

April, 2022 – Keymed Biosciences (2162 HK) announced that the U S Food and Drug Administration (FDA) granted CMG

2022-04-19
More

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the FDA

Keymed Biosciences announced that its new drug candidate CMG901 (the “Claudin 18 2 antibody drug conjugates”) for

2022-04-11
More

Keymed Biosciences released positive result from Phase II clinical trial of CM310 at CRSwNP

March 30, 2022, Keymed Biosciences is pleased to announce that Phase II clinical study of its self-developed Clas

2022-03-30
More

Keymed Biosciences Releases 2021 Annual Results

March 29, 2022, Chengdu, China - Keymed Biosciences Inc (HKEX Code: 02162) released 2021 annual results BUSINESS

2022-03-29
More

Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect

March 7, 2022, Chengdu, China -Keymed Biosciences Inc (2162 HK) is pleased to announce that the shares of the C

2022-03-07
More

Keymed Bio Joins Hang Seng Family of Indexes

February 18, 2022, Hong Kong – According to the quarterly review results of Hang Seng Family of Indexes, Keymed

2022-02-18
More

Keymed and InnoCare Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355

Chengdu, Jan. 18, 2022 –Keymed Biosciences (HKEX: 02162) and InnoCare Pharma (HKEX: 09969) jointly announced today...

2022-01-18